BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company reached on September 17th.
Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.
DPA International on MSN4d
BioNTech and Pfizer to pay Covid-19 vaccine settlements in USThe German pharmaceutical company BioNTech announced on Friday that it has reached settlements in the US to resolve a ...
German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate ...
Seeking Alpha on MSN4d
BioNTech inks $1B settlements with NIH and Penn to resolve COVID vaccine royalty claimsBioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine ...
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.
Pharma majors like BioNTech in Germany and Pfizer in the United States have made profits in billions of dollars in selling ...
BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback